Precision medicine in the treatment stratification of AML patients: Challenges and progress

Ines Lohse, Kurt Statz-Geary, Shaun P Brothers, Claes R Wahlestedt

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

Recent advances in high throughput technologies have led to the generation of vast amounts of clinical data and the development of personalized medicine approaches in acute myeloid leukemia (AML). The ability to treat cancer patients based upon their individual molecular characteristics or drug sensitivity profiles is expected to significantly advance cancer treatment and improve the long-term survival of patients with refractory AML, for whom current treatment options are restricted to palliative approaches. The clinical development of omics-based and phenotypic screens, however, is limited by a number of bottlenecks including the generation of cost-effective high-throughput data, data interpretation and integration of multiple approaches, sample availability, clinically relevant timelines, and the development and education of multidisciplinary teams. Recently, a number of small clinical trials have shown survival benefits in patients treated based on personalized medicine approaches. While these preliminary studies are encouraging, larger trials are needed to evaluate the utility of these technologies in routine clinical settings.

Original languageEnglish (US)
Pages (from-to)37790-37797
Number of pages8
JournalOncotarget
Volume9
Issue number102
StatePublished - Dec 1 2018

Keywords

  • AML
  • Ex vivo drug sensitivity screens
  • Omics-based screens
  • Phenotypic screens
  • Precision medicine

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Precision medicine in the treatment stratification of AML patients: Challenges and progress'. Together they form a unique fingerprint.

  • Cite this